Karyopharm Therapeutics, Inc. (KPTI)
0.8022
-0.06
(-7.45%)
USD |
NASDAQ |
Oct 02, 16:00
0.8487
+0.05
(+5.80%)
After-Hours: 20:00
Karyopharm Therapeutics EPS Diluted (Quarterly) : -2.316 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.316 |
| March 31, 2026 | -1.236 |
| December 31, 2025 | -5.708 |
| September 30, 2025 | -3.821 |
| June 30, 2025 | -4.322 |
| March 31, 2025 | -2.77 |
| December 31, 2024 | -3.668 |
| September 30, 2024 | -0.2566 |
| June 30, 2024 | -0.1982 |
| March 31, 2024 | -0.3236 |
| December 31, 2023 | -0.3645 |
| September 30, 2023 | -0.3016 |
| June 30, 2023 | -0.2857 |
| March 31, 2023 | -0.3007 |
| December 31, 2022 | -0.4282 |
| September 30, 2022 | -0.4529 |
| June 30, 2022 | -0.616 |
| March 31, 2022 | -0.5337 |
| December 31, 2021 | 0.4457 |
| September 30, 2021 | -0.6866 |
| June 30, 2021 | -0.7126 |
| March 31, 2021 | -0.7705 |
| December 31, 2020 | -0.5889 |
| September 30, 2020 | -0.7282 |
| June 30, 2020 | -0.6339 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.7827 |
| December 31, 2019 | -0.7612 |
| September 30, 2019 | -0.6662 |
| June 30, 2019 | -0.7126 |
| March 31, 2019 | -1.087 |
| December 31, 2018 | -0.958 |
| September 30, 2018 | -0.7936 |
| June 30, 2018 | -0.60 |
| March 31, 2018 | -0.7753 |
| December 31, 2017 | -0.80 |
| September 30, 2017 | -0.65 |
| June 30, 2017 | -9.60 |
| March 31, 2017 | -10.71 |
| December 31, 2016 | -0.65 |
| September 30, 2016 | -0.69 |
| June 30, 2016 | -0.84 |
| March 31, 2016 | -0.75 |
| December 31, 2015 | -0.81 |
| September 30, 2015 | -0.85 |
| June 30, 2015 | -0.92 |
| March 31, 2015 | -0.74 |
| December 31, 2014 | -0.79 |
| September 30, 2014 | -0.61 |
| June 30, 2014 | -0.55 |
| March 31, 2014 | -0.46 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Madrigal Pharmaceuticals, Inc. | -1.988 |
| Relay Therapeutics, Inc. | -0.4127 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -67.02M |
| Revenue (Quarterly) | 33.43M |
| Total Expenses (Quarterly) | 100.46M |
| Enterprise Value | 209.28M |
| Gross Profit Margin (Quarterly) | 96.75% |
| Profit Margin (Quarterly) | -200.5% |
| Earnings Yield | -1.63K% |
| Normalized Earnings Yield | -1326.76 |